According to a new guideline from the American Society for Gastrointestinal Endoscopy (ASGE) regarding the management of antithrombotic agents for endoscopy, aspirin and/or NSAIDs may be continued for all elective endoscopic procedures. When high-risk procedures are planned, clinicians may elect to discontinue aspirin and/or NSAIDs for five to seven days before the procedure, depending on the underlying indication for antiplatelet therapy. For patients on temporary anticoagulation therapy (e.g., warfarin for deep venous thrombosis), it is suggested that elective endoscopic procedures be deferred until antithrombotic therapy is completed.
A non-absorbed, oral co-polymer therapy under development by Midway Pharmaceuticals demonstrated the ability to protect against damage to healthy gastrointestinal tissues and to prevent lethal bacterial infections in animal models of radiation damage. The results suggest the compound, a high molecular weight co-polymer of polyethylene glycol (PEG), may provide a new way to prevent serious GI side effects of radiation in patients receiving fractionated radiotherapy for abdominal cancers or in accidental exposures to harmful radiation. The new results are published online and in the December issue of the American Journal of Physiology by John Alverdy, MD, Director, Center for Surgical Infection Research, University of Chicago, Pritzker School of Medicine and colleagues at the University of Chicago, and University of Arkansas for Medical Sciences and Surgical Service.
Santarus, Inc. (NASDAQ: SNTS), a specialty biopharmaceutical company, today announced that its collaboration partner, Cosmo Technologies Ltd., a subsidiary of Cosmo Pharmaceuticals SpA (SIX: COPN), has completed enrollment of 514 patients in the European Phase III clinical trial to evaluate budesonide MMX® administered over eight weeks for the induction of remission of mild or moderate active ulcerative colitis. This is the first of two induction phase clinical trials being conducted as part of the budesonide MMX Phase III clinical program. Santarus and Cosmo expect to report preliminary top line results from the European Phase III clinical trial in the first half of 2010.
Performing surgical operations without leaving scars has ceased to be a chimera and has become a reality. This is demonstrated by the recent surgical advances made using NOTES (Natural Orifice Transluminal Endoscopy Surgery), an innovative surgical approach that allows surgical access using the body's natural orifices. The results are all advantageous for the patient: lack of scars, shorter hospital stay and faster recovery. Currently, this type of minimally-invasive surgery is still in the research and development stage. Surgery through the mouth and vagina has been successfully used, but the transanal route (through the anus) is less utilized.
Center For Digestive Care Established At NewYork-Presbyterian Weill Cornell, Dedicated To Innovative And Coordinated Patient Care
The Center for Digestive Care at NewYork-Presbyterian Hospital/Weill Cornell Medical Center has been established with a mission to provide high-quality patient care, research and education for all aspects of digestive disease. It offers innovative treatments and coordinated care for conditions ranging from gastrointestinal reflux and hepatitis C to colon cancer and metabolic surgery, a new field that focuses on reversing Type 2 diabetes. The Center was made possible through gifts totaling $65 million from The Leona M. and Harry B. Helmsley Charitable Trust to NewYork-Presbyterian Hospital/Weill Cornell Medical Center -- among the largest earmarked specifically for advancing treatment of digestive diseases.
Saint Louis University Hospital Is One Of First To Perform Total Abdominal Colectomy Via Single-incision Laparoscopic Surgery
Building upon the momentum and success of its rapidly growing single-incision laparoscopic surgery program, Saint Louis University Hospital recently performed one of the first total abdominal colectomies, including reconstruction of the intestinal tract by reconnection of the remaining small intestine to the rectum, via single-incision laparoscopy. This procedure is a critical advancement in minimally-invasive surgery. Ovunc Bardakcioglu, M.D., a gastrointestinal surgeon at SLU Hospital and director of the hospital's single-incision laparoscopic program, performed the procedure on a 64-year-old male with colon cancer, extracting approximately 40 inches of colon through a four-centimeter incision below the bellybutton region.